Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2768-2774

  Marier, Jean Francois ^a   Trinh, MyMy ^a   Pheng, Leng Hong ^a   Palleja, Sandra M ^b   Martin, David E ^b  

^a Pharsight A Certara Company   (Canada)

^b Tobira Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENICRIVIROC; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AFRICAN AMERICAN; AGED; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARGENTINA; ARTICLE; ASIAN; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; SYSTEMIC CIRCULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNITED STATES; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; AZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HIV-1; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTORS, CCR5;

EID: 79956334445     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00713-10     Document Type: Article

References (22)

1. Cohen, C., et al. 2007. Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days of monotherapy, abstr. TUAB106. Abstr. 4th Int. AIDS Soc. Conf. HIV Pathogenesis Treatment Prev.
2. Craig, C., et al. 2010. Mechanisms of virologic failure with maraviroc in treatment-naïve HIV-1-infected patients through 96 weeks, poster 536. Abstr. 17th Conf. Retrovir. Opportunistic Infect.
3. Esté, J. A. 2002. Sch-351125 and Sch-350634. Schering Plough. Curr. Opin. Invest. Drugs 3:379-383.
4. Fätkenheuer, G., et al. 2005. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV 1. Nat. Med. 11:1170-1172.
5. Feinberg, J., and A. J. Japour. 2003. Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection. Clin. Infect. Dis. 36:201-206.
6. Harrigan, P. R., et al. 2009. Screening for HIV tropism using populationbased V3 genotypic analysis: a retrospective virological outcome analysis using stored plasma screening samples from MOTIVATE-1, abstr. WELBA101. Abstr. 5th Int. AIDS Soc. Conf., Cape Town, South Africa, 19 to 22 July 2009.
7. Hunt, P., et al. 2007. Longitudinal evaluation of viral co-receptor tropism switches among HIV-infected patients with drug resistant viremia, poster 619. Abstr. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA, 25 to 28 February 2007.
8. Jubb, R., et al. 2010. CCR5-tropic resistance to maraviroc is uncommon even among patients on functional MVC monotherapy or with ongoing low-level replication, poster 639. Abstr. 17th Conf. Retrovir. Opportunistic Infect.
9. Lalezari, J., et al. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naïve subjects. J. Acquir. Immune Defic. Syndr., in press.
10. McGovern, R. A., et al. 2010. Population-based sequencing of the V3-loop is comparable to the enhanced sensitivity Trofile assay (ESTA) in predicting virologic response to maraviroc of treatment-naïve patients in the MERIT trial, abstr. 92. Abstr. 17th Conf. Retrovir. Opportunistic Infect, San Francisco, CA, 16 to 19 February 2010.
11. Moore, J. P., and D. R. Kuritzkes. 2009. A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr. Opin. HIV AIDS 4:118-124.
12. Palleja, S., et al. 2009. The multiple-dose safety, tolerability, and pharmacokinetics of TBR-652, a chemokine receptor 5 (CCR5) antagonist, in healthy volunteers, abstr. A1-1308. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September 2009.
13. Rosario, M. C., B. Poland, J. Sullivan, M. Westby, and E. van der Ryst. 2006. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. J. Acquir. Immune Defic. Syndr. 42:183-191.
14. Schlecht, H. P., S. Schellhorn, B. J. Dezube, and J. M. Jacobson. 2008. New approaches in the treatment of HIV/AIDS-focus on maraviroc and other CCR5 antagonists. Ther. Clin. Risk Manag. 4:473-485.
15. Shafer, R. W., and J. M. Shapiro. 2008. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 10:67-84.
16. Shepherd, J. C., et al. 2008. Emergence and persistence of CXCR4-tropic HIV in a population of men from the Multicenter AIDS Cohort Study. J. Infect. Dis. 198:1104-1112.
17. Suleiman, J., et al. 2010. Vicriviroc in combination therapy with an optimized background regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. J. Infect. Dis. 201:590-599.
18. Trkola, A., et al. 2002. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. U. S. A. 99:395-400.
19. Waters, L., et al. 2008. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin. Infect. Dis. 46:1617-1623.
20. Westby, M., and E. van der Ryst. 2005. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir. Chem. Chemother. 16:339-354.
21. Westby, M., et al. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV 1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80:4909-4920.
22. Whitcomb, J. M., et al. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51:566-575.